NCT02977065View on ClinicalTrials.gov

To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

December 30, 2017

Study Completion Date

January 30, 2018

Conditions
Dyslipidemias
Interventions
DRUG

Atorvastatin 20mg

PO daily for 4weeks

DRUG

Atorvastatin 20 mg + CKD-519 50 mg

PO daily for 4weeks

DRUG

Atorvastatin 20 mg + CKD-519 100 mg

PO daily for 4weeks

DRUG

Atorvastatin 20 mg + CKD-519 200 mg

PO daily for 4weeks

DRUG

Rosuvastatin 10 mg

PO daily for 4weeks

DRUG

Rosuvastatin 10 mg + CKD-519 100 mg

PO daily for 4weeks

Trial Locations (1)

Unknown

Not provided, Adelaide

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY